Keyword → AZN

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.

OPKO Health Schedules Q4 Earnings Report, Shares React to Upcoming Guidance

OPKO Health announced plans to release its fourth-quarter and full-year 2025 financial results later this month, expected to include commentary on future revenue and profitability. The upcoming earnings call could influence sentiment among healthcare and biotech investors amid broader market volatility.

London’s FTSE 100 Dips as Standard Chartered and BP Weigh on Markets

The FTSE 100 index slipped on February 10, pressured by sharp share price declines at Standard Chartered and BP, with broader investor caution amid earnings and governance concerns. While some heavyweight stocks rose, energy sector headwinds and executive turnover unsettled sentiment in European markets.

Philips Reports 2025 Results With Margin Expansion and 2026 Outlook Targets

Royal Philips published its full-year 2025 financial results, highlighting accelerated growth, expanding profit margins and robust cash flow. The company also unveiled strategic targets for 2026-2028, emphasizing innovation and operational efficiency across health technology segments.

Market Focus Shifts to Jobs, Inflation and Retail Data as Earnings Calendar Warms

Investors are bracing for a key week of economic data and corporate earnings, with delayed January jobs numbers, CPI inflation, and December retail sales due for release. Major technology and consumer firms are also reporting results, highlighting the intersection of macro indicators and corporate performance. These releases are expected to shape expectations for monetary policy and market direction in coming weeks.

London’s FTSE 100 Index Declines on Sector Weakness Despite Broader Risk Appetite

The FTSE 100 index fell 0.4% on January 28, 2026, pressured by declines in healthcare and banking stocks, offset partially by gains in the FTSE 250 and energy sectors. Pharmaceutical giants and major lenders slid amid mixed earnings data and profit taking, while miners and energy companies found support. Market participants maintained focus on upcoming earnings and U.S. monetary policy developments influencing global sentiment.